Hepatitis C
Authors: Janice H. Jou, Andrew J. Muir
Journal: Annals of Internal Medicine (2012)

In the Clinic4 December 2012Hepatitis CJanice H. Jou, MD, Andrew J. Muir, MD, Deborah Cotton, MD, PhD, Darren Taichman, MD, MPH, and Sankey Williams, MDJanice H. Jou, MDSearch for more papers by this author, Andrew J. Muir, MDSearch for more papers by this author, Deborah Cotton, MD, PhDSearch for more papers by this author, Darren Taichman, MD, MPHSearch for more papers by this author, and Sankey Williams, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-157-11-201212040-01006 SectionsSupplemental MaterialAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Editor's Note: This issue of In the Clinic has been updated.The approach to hepatitis C virus (HCV) infection has undergone tremendous change in the past 2 years. The first-generation protease inhibitors have been approved for treatment of genotype 1 infection, leading to sustained virologic response (SVR) rates of 68%–75% for treatment-naïve patients (1, 2). Other direct-acting antiviral agents are being developed, and it is expected that treatments for all genotypes will have better response rates and side effect profiles in coming years. In this context, the Centers for Disease Control and Prevention (CDC) recently updated its HCV screening guidelines ...References1. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405-16. Google Scholar2. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-206. Google Scholar3. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Ward JW. Hepatitis C virus testing of persons born during 1945 to 1965: Recommendations from the Centers for Disease Control and Prevention. Ann Intern Med. 2012;157:816-21. Google Scholar4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-14. Google Scholar5. Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2010; 8:192-9. [PMID: 19879972] Google Scholar6. Hwang LY, Kramer JR, Troisi C, et al. Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population. Hepatology. 2006;44:341-51. Google Scholar7. Lanphear BP, Linnemann CC Jr., Cannon CG, DeRonde MM, Pendy L, Kerley LM. Hepatitis C virus infection in health care workers: risk of exposure and infection. Infect Control Hosp Epidemiol. 1994;15:745-50. Google Scholar8. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36:3-10. Google Scholar9. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Recomm Rep. 2001;50:1-43. Google Scholar10. Macedo de Oliveira A, White KL, Leschinsky DP, et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med. 2005;142:898-902. Google Scholar11. Hellinger WC, Bacalis LP, Kay RS, Thompson ND, Xia GL, Lin Y, et al. Health care-associated hepatitis C virus infections attributed to narcotic diversion. Ann Intern Med. 2012;156:477-82. Google Scholar12. Terrault NA. Sexual activity as a risk factor for hepatitis C. Hepatology. 2002;36(5 Suppl 1):S99-105. Google Scholar13. Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men—New York City, 2005-2010. MMWR Morb Mortal Wkly Rep. 2011;60:945-50. Google Scholar14. Danta M, Brown D, Bhagani S, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS. 2007;21(8):983-91. Google Scholar15. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology. 2002;36(5 Suppl 1):S106-13. Google Scholar16. Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health. 2000;77:369-82. Google Scholar17. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002. Hepatology. 2002;36(5 Suppl 1):S3-20. Google Scholar18. Vandelli C, Renzo F, Romano L, Tisminetzky S, De Palma M, Stroffolini T, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol. 2004;99:855-9. Google Scholar19. Shapiro CN. Transmission of hepatitis viruses. Ann Intern Med. 1994;120:82-4. Google Scholar20. Lock G, Dirscherl M, Obermeier F, et al. Hepatitis C contamination of toothbrushes: myth or reality? J Viral Hepat. 2006;13:571-3. Google Scholar21. Sawayama Y, Hayashi J, Kakuda K, et al. Hepatitis C virus infection in institutionalized psychiatric patients: possible role of transmission by razor sharing. Dig Dis Sci. 2000;45:351-6. Google Scholar22. Siegel JD, Rhinehart E, Jackson M, Chiarello L. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health care Settings. Am J Infect Control. 2007;35(10 Suppl 2):S65-164. Google Scholar23. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby MO, Di Bisceglie AM. Testing for hepatitis C virus infection should be routine for persons at increased risk for infection. Ann Intern Med. 2004;141:715-7. Google Scholar24. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2012;156:263-70. Google Scholar25. Vrielink H, Reesink HW, van den Burg PJ, et al. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients. Transfusion. 1997;37:845-9. Google Scholar26. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798-801. Google Scholar27. Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol. 2005;42:266-74. Google Scholar28. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol. 2009;44(Suppl 19):96-101. Google Scholar29. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49:1017-44. Google Scholar30. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-74. Google Scholar31. Ghany MG et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guieline by the American Associaion for the Study of Liver Diseases. Hepatology, 2011;54:1433-1444. Google Scholar32. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol. 1999;31 Suppl 1:9-16. Google Scholar33. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069-75. Google Scholar34. Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41:48-54. Google Scholar35. Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102:2589-600. Google Scholar36. Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology. 1998;28:805-9. Google Scholar37. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther. 2005;12:133-41. Google Scholar38. Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev. 2007:CD003620. Google Scholar39. Hawke RL, Schrieber SJ, Soule TA, et al. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol. 2010;50:434-49. Google Scholar40. Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol. 2007;5:408-16. Google Scholar41. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401. Google Scholar42. Litwin AH, Harris KA, Jr., Nahvi S, et al. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat. 2009;37:32-40. Google Scholar43. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361:580-93. Google Scholar44. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-71. Google Scholar45. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52. Google Scholar46. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol. 2004;99:1733-7. Google Scholar47. Legrand-Abravanel F, Sandres-Saune K, Barange K, et al. Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis. 2004;189:1397-400. Google Scholar48. Fung J, Lai CL, Hung I, et al. Chronic hepatitis C virus genotype 6 infection: response to pegylated interferon and ribavirin. J Infect Dis. 2008;198:808-12. Google Scholar49. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-7. Google Scholar50. Jakiche R, Borrego ME, Raisch DW, Gupchup GV, Pai MA, Jakiche A. The cost-effectiveness of two strategies for vaccinating US veterans with hepatitis C virus infection against hepatitis A and hepatitis B viruses. Am J Med Sci. 2007;333:26-34. Google Scholar51. General recommendations on immunization—recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-64. Google Scholar52. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep. 2010;59:1102-6. Google Scholar53. Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci. 2007;52:732-6. Google Scholar54. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207-17. Google Scholar55. Meyer SD, Dierynck I, Ghys A, et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the realize trial. Hepatology. 2012 Jul 16. [Epub ahead of print] [PMID:22806681] Google Scholar56. Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366:216-24. Google Scholar57. Victrelis (boceprevir) prescribing information. www.accessdata.fda.gov/scripts/cder/drugsatfda/; April 2012. Google Scholar58. Incivek (telaprevir) prescribing information. www.accessdata.fda.gov/scripts/cder/drugsatfda/. March 2012. Google Scholar59. Eltrombopag prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2011/022291s006lbl.pdf 2011. Google Scholar60. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med. 2007;357:2227-36. Google Scholar61. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology. 2009;50:1709-18. Google Scholar62. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280-8. Google Scholar63. Innes HA, Hutchinson SJ, Allen S, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 2011;54:1547-58. Google Scholar64. Murray KF, Carithers RL, Jr. AASLD pracice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-32. Google Scholar65. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-2. Google Scholar66. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130:417-22. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byHepatitis C VirusArthur Kim, MDHepatitis C, Disease and Its Management: A Cost-Effectiveness Analysis of the New Generation Oral Protease Inhibitors"Test, Listen, Cure" (TLC) Hepatitis C Community Awareness CampaignDendritic cell maturation in HCV infection: Altered regulation of MHC class I antigen processing-presenting machineryPrevalence of occult hepatitis C infection in chronic hemodialysis and kidney transplant patients 4 December 2012Volume 157, Issue 11Page: ITC6-1KeywordsBiopsyCirrhosisDrugsHepatitis CLiverLiver diseasesLiver fibrosisProtease inhibitorsRNASystemic vascular resistance ePublished: 4 December 2012 Issue Published: 4 December 2012 Copyright & PermissionsCopyright © 2012 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...